-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…
MUNICH, Aug. 4, 2025 /PRNewswire/ -- Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider,…
New York City, NY, July 27, 2025 (GLOBE NEWSWIRE) -- A recent survey shows that TestoPrime is widely regarded by…
ZUG, Switzerland, July 23, 2025 /PRNewswire/ -- Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II…
Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 /PRNewswire/ -- Berlin…
SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC:…
July 11, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls…
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders…
July 10, 2025 16:30 ET | Source: NKGen Biotech, Inc. SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen…